Abaxis Declares Quarterly Cash Dividend
Get Alerts ABAX Hot Sheet
Join SI Premium – FREE
UNION CITY, Calif., Nov. 3, 2015 /PRNewswire/ -- The Board of Directors of Abaxis, Inc. (NasdaqGS: ABAX), has declared a cash dividend of $0.11 per common share. The dividend will be payable on December 17, 2015 to all shareholders of record at the close of business on December 3, 2015.
Abaxis' previous quarterly dividend of $0.11 per common share was paid on September 17, 2015. Future dividends will be subject to approval by our Board of Directors.
About Abaxis
Abaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets. We provide leading edge technology and tools that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. For more information, visit http://www.abaxis.com.
|
Contact: |
Abaxis, Inc. |
Lytham Partners, LLC |
|
Clint Severson |
Joe Dorame, Robert Blum and Joe Diaz | |
|
Chief Executive Officer |
602-889-9700 | |
|
510-675-6500 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abaxis-declares-quarterly-cash-dividend-300171010.html
SOURCE Abaxis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nocpix Nature Launches Rovex, a Large-Screen Thermal Solution for Faster Bird Discovery
- Official Trump (TRUMP) Coin Price Prediction: 98% Below ATH While Pepeto Races Toward
- Reconnect, a Contender for Best Resort in Sulawesi, Plans 2027 Expansion
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share